Social Media

AMVUTTRA (vutrisiran) is a prescription medicine that treats the:cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to…

It's Super Cardiology Monday at #NMA2026!On Monday, July 27, ABC teams up with the NMA Internal Medicine Section for a full day of cardiology programming — three…

My husband has been on Amvuttra plus Vydamax and received a letter from the insurance company that they no longer will pay for the vydamax.  He has cardiac…

New insights into the heart-kidney connection in ATTR-CM.Dr. Jeffrey Testani and I discuss new analyses showing that acoramidis was associated with early and…

Medicine Supply Shortage Alert: Tegsedi® (inotersen) The European Medicines Agency (EMA) has announced that Tegsedi® (inotersen) will become unavailable in the…

Understanding the diverse treatment options for ATTR amyloidosis is essential for managing this complex condition, from gene-silencing therapies to supportive care…

Recent clinical trial findings reveal promising news for the community. A targeted treatment has been shown to rapidly and consistently lower the disease-causing…

🚨 Medicine Supply Shortage Alert: Tegsedi® (inotersen) The European Medicines Agency (EMA) has announced that Tegsedi® (inotersen) will become unavailable in…

Reverse Heart damage in ATTR-CMhttps://amyloidosisnewstoday.com/.../experimental.../...

Many thanks to British Journal of Cardiology for giving me this platform to discuss a topic that is hugely important yet underreported 🙏🏾 Cardiac ATTR amyloidosis…